| HOME >> BIOLOGY >> TECHNOLOGY |
INDIANAPOLIS, Oct. 5, 2011 /PRNewswire/ -- BioCrossroads today announced the receipt of a two-year $2.8 million grant from Lilly Endowment Inc. The grant will fund a range of charitable, educational and scientific activities through 2013 as BioCrossroads continues to build upon Indiana's signature strengths in the life sciences.
"As BioCrossroads approaches our 10-year anniversary in early 2012, we recognize that Lilly Endowment's significant investment in our initiative has been a game-changer for the success of Indiana's life sciences sector and, therefore, for our entire community," said D. Craig Brater, MD, chairman of the board of BioCrossroads. "As detailed in a recent Battelle report on the progress of Indiana's life sciences cluster, Indiana has seen a decade of substantial growth and tremendous progress across a wide range of nationally significant indicators. This is in large part due to the efforts of BioCrossroads and the major support of its founding stakeholders, especially Lilly Endowment."
Indiana's life sciences sector has received national recognition as a life sciences center. In June 2009, The Economist said, "Though every state wants to be a hub in the life sciences, Indiana actually is one..." More recently, an August Wall Street Journal article called Indianapolis a hotbed of activity for the life sciences, citing the state's 825 life sciences companies and 8,800 new jobs.
Grants from Lilly Endowment for the BioCrossroads initiative (now totaling more than $25 million) go to the CICP Foundation, which also supports other eligible charitable, educational and scientific initiatives and activities of the Central Indiana Corporate Partnership. Since its inception, BioCrossroads has focused on projects that work with existing assets and connect them to the community in new ways, leading to the creation of eight collaborative enterprises, such as the Indiana Health Information Exchange, OrthoWorx and the Data
'/>"/>
| SOURCE BioCrossroads Copyright©2010 PR Newswire. All rights reserved |